Historical Valuation
Co-Diagnostics Inc (CODX) is now in the Fair zone, suggesting that its current forward PS ratio of 17.97 is considered Fairly compared with the five-year average of 6.07. The fair price of Co-Diagnostics Inc (CODX) is between 0.45 to 7.24 according to relative valuation methord.
Relative Value
Fair Zone
0.45-7.24
Current Price：6.12
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Co-Diagnostics Inc (CODX) has a current Price-to-Book (P/B) ratio of 0.22. Compared to its 3-year average P/B ratio of 0.42 , the current P/B ratio is approximately -46.64% higher. Relative to its 5-year average P/B ratio of 1.21, the current P/B ratio is about -81.46% higher. Co-Diagnostics Inc (CODX) has a Forward Free Cash Flow (FCF) yield of approximately -281.87%. Compared to its 3-year average FCF yield of -106.01%, the current FCF yield is approximately 165.88% lower. Relative to its 5-year average FCF yield of -56.18% , the current FCF yield is about 401.73% lower.
P/B
Median3y
0.42
Median5y
1.21
FCF Yield
Median3y
-106.01
Median5y
-56.18
Competitors Valuation Multiple
AI Analysis for CODX
The average P/S ratio for CODX competitors is 3.62, providing a benchmark for relative valuation. Co-Diagnostics Inc Corp (CODX.O) exhibits a P/S ratio of 17.97, which is 396.95% above the industry average. Given its robust revenue growth of -77.32%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CODX
1Y
3Y
5Y
Market capitalization of CODX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CODX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CODX currently overvalued or undervalued?
Co-Diagnostics Inc (CODX) is now in the Fair zone, suggesting that its current forward PS ratio of 17.97 is considered Fairly compared with the five-year average of 6.07. The fair price of Co-Diagnostics Inc (CODX) is between 0.45 to 7.24 according to relative valuation methord.
What is Co-Diagnostics Inc (CODX) fair value?
CODX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Co-Diagnostics Inc (CODX) is between 0.45 to 7.24 according to relative valuation methord.
How does CODX's valuation metrics compare to the industry average?
The average P/S ratio for CODX's competitors is 3.62, providing a benchmark for relative valuation. Co-Diagnostics Inc Corp (CODX) exhibits a P/S ratio of 17.97, which is 396.95% above the industry average. Given its robust revenue growth of -77.32%, this premium appears unsustainable.
What is the current P/B ratio for Co-Diagnostics Inc (CODX) as of Jan 09 2026?
As of Jan 09 2026, Co-Diagnostics Inc (CODX) has a P/B ratio of 0.22. This indicates that the market values CODX at 0.22 times its book value.
What is the current FCF Yield for Co-Diagnostics Inc (CODX) as of Jan 09 2026?
As of Jan 09 2026, Co-Diagnostics Inc (CODX) has a FCF Yield of -281.87%. This means that for every dollar of Co-Diagnostics Inc’s market capitalization, the company generates -281.87 cents in free cash flow.
What is the current Forward P/E ratio for Co-Diagnostics Inc (CODX) as of Jan 09 2026?
As of Jan 09 2026, Co-Diagnostics Inc (CODX) has a Forward P/E ratio of -0.42. This means the market is willing to pay $-0.42 for every dollar of Co-Diagnostics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Co-Diagnostics Inc (CODX) as of Jan 09 2026?
As of Jan 09 2026, Co-Diagnostics Inc (CODX) has a Forward P/S ratio of 17.97. This means the market is valuing CODX at $17.97 for every dollar of expected revenue over the next 12 months.